PURPOSE: To evaluate 2-year outcomes following intravitreal bevacizumab (IVB) as monotherapy for @entity146 posterior @entity989 (APROP). METHODS: Medical records of 40 @entity1 were retrospectively reviewed. Group I included @entity1 who had received IVB injections for APROP. Group II included @entity1 who underwent laser treatment for APROP. Anatomic and refractive outcomes and the presence of @entity9340 and strabismus were assessed at follow-up examinations. RESULTS: Group I included 48 eyes of 25 @entity1 (11 males) with a mean gestational age (GA) of 26.40    1.82 weeks and a mean birth weight (BW) of 901.40    304.60 g. Group II included 30 eyes of 15 @entity1 (6 males) with a mean GA of 27.30    1.82 weeks and a mean BW of 941.00    282.48 g. GA, BW, and gender distributions were similar between groups (P=0.187, P=0.685, and P=1.000, respectively). @entity2516 were significantly less myopic in group I (0.42    3.42 D) than in group II (-6.66    4.96 D) at 2 years (P=0.001). Significantly higher rates of @entity9340 and strabismus were observed in group II than in group I (P=0.009 and P=0.036, respectively). CONCLUSIONS: The study demonstrated that IVB monotherapy can be useful in the treatment of APROP. The decreased incidence of early unfavorable refractive and functional outcomes in the IVB group compared with the laser group showed a potential benefit for @entity1 treated with IVB, and this needs to be better evaluated in future prospective studies.

Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for XXXX posterior @entity989 .

@entity1 :: ('9606', 'Species') :: ['patients', 'infants'] @entity2516 :: ('MESH:D012030', 'Disease') :: ['Refractive errors'] @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive'] @entity9340 :: ('MESH:D015858', 'Disease') :: ['anisometropia'] @entity989 :: ('MESH:D012164', 'Disease') :: ['retinopathy of prematurity']
@entity146 :: (MESH:D001523,Disease) :: ['aggressive']
